Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Altimmune Stock

Price
Target price
€5.77

€5.77

-3.450%
-0.207
-3.450%
€13.72
 
19.07.24 / Tradegate WKN: A2N5Z6 / Symbol: ALT / Name: Altimmune / Stock / Micro Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Altimmune in the next few years
Wizard

Altimmune Stock

Heavy losses for Altimmune today as the stock fell by -€0.207 (-3.450%).
With 10 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 5.77 € the target price of 13 € shows a potential of 125.38% for Altimmune which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Altimmune stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.
What does Altimmune do?

Pros and Cons of Altimmune in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-25

Upon first glance, the financials of Altimmune, Inc. (ALT) seem to present a mixed picture. The company has managed to maintain a relatively stable asset base over the past few years, but a consistent net loss in its income statements indicates ongoing challenges in operational efficiency. In order to provide a more comprehensive evaluation, this article will delve into the pros and cons of the company's financial performance.

Stable Total Assets: A closer look at the balance sheets reveals that Altimmune's total assets have remained relatively consistent throughout the years, with USD 206.9 million in 2022, USD 218.9 million in 2021, and USD 245.1 million in 2020. This stability suggests that the company is maintaining its asset base and could indicate financial stability.

High Net Working Capital: ALT's net working capital is quite strong, showing a surplus of resources to meet short-term obligations. In 2022, their net working capital was USD 175.8 million, indicating a healthy liquidity position.

Show more

Comments

Prediction Buy
Perf. (%) -15.06%
Target price 18.686
Change
Ends at 25.06.25

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

B. Riley 
0
Report Share
25.06.24
Prediction Buy
Perf. (%) -2.67%
Target price 23.370
Change
Ends at 21.06.25

Altimmune, Inc. (NASDAQ: ALT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $25.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

Piper Sandler 
0
Report Share
21.06.24
Prediction Buy
Perf. (%) -15.57%
Target price 11.105
Change
Ends at 14.05.25

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
14.05.24
Show more
Not a member yet? Sign up for free!

News

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?: https://g.foolcdn.com/editorial/images/783710/researchers-work-in-the-lab.jpg
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the

TheMotleyFool 
0 20.07.24
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug: https://www.marketbeat.com/logos/articles/med_20240708142435_eli-lilly-stock-leads-the-glp-1-race-with-its-trip.jpg
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug

Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo

MarketBeat 
0 09.07.24
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?: https://www.marketbeat.com/logos/articles/med_20240630174606_charty-alt.jpg
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic

MarketBeat 
0 03.07.24